2-methyl-2,8-diazaspiro[4.5]decane dihydrochloride, 95.0%, 5g

CRBN modulator-1, 10mg

3-Chloro-N-methylpropan-1-amine hydrochloride, 95.0%, 25g

4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, 97.0%, 25mg

1,8-diazabiciclo[5.4.0]undec-7-eno (DBU), mínimo 98 %, para síntesis, 500 ml, envase de vidrio

(5S,8S,11S,12R)-11-((S)-sec-Butyl)-1-(9H-fluoren-9-yl)-5,8-diisopropyl-12-methoxy-4,10-dimethyl-3,6,9-trioxo-2-oxa-4,7,10-triazatetradecan-14-oic acid, 98%, 1g

2-Chloro-5H-pyrrolo[2,3-b]pyrazine, 95.0%, 250mg

(E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide, 95.0%, 250mg

Benzyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate, 95.0%, 1g

(4-((4-Cyanobenzyl)oxy)phenyl)boronic acid, 98+%, 250mg

BROMO-PEG2-BROMIDE, 95.0%, 250mg

1-[1-(3-methylphenyl)-1H-pyrazol-4-yl]ethanone, 95.0%, 25g

4'-(Trifluoromethoxy)acetophenone, 98.0%, 500g